Haemophilia and Haemostasis Management

• Healthcare Professionals
•  
• Patients
•  
• Investors
•  
• Media
•  
• R&D
•  
• Jobs
•  
• Sustainability
•  
• About us

• R&D at a glance
• About R&D
• Pipeline
• Partnering
  • Why partner with us?
  • Being partner with us
  • Diabetes
  • Protein Delivery
  • Haemophilia
  • Growth disorders
  • Inflammation
  • Partnerships
  • Protein expertise
  • Clinical research partnerships
  • Novo Nordisk Biotech Fund
  • Contact us
• Scientific publications
• Bioethics
• From idea to patient
• Fellowships
• Novo Nordisk Trials
• Contact us

• 
• Print

Haemophilia

Our ambition

Our ambition is to change possibilities for people with haemophilia and inhibitors. Every step of our journey is focused on improving treatment options, providing better access to care and following through on our commitment to understand the needs of people with haemophilia.

Our partnering focus

We seek partners and opportunities within prevention and treatment of bleeding in people with haemophilia:

• Improvement of current therapies for people with inhibitors, including prophylaxis
• Improvement of FVIII and FIX based therapies for people with haemophilia A or B, including long-acting prophylaxis
• Novel non-replacement therapies that improve haemostasis

Biopharmaceuticals Research Unit

For other enquiries

Contact

For further information please contact Biopharmaceuticals Sourcing

Download

Please download the Novo Nordisk:
Partnering folder

Back to top